Endomicroscopy can be added after chromoendoscopy to clarify whether standard biopsies are still needed. This smart biopsy concept can increase the diagnostic yield of intraepithelial neoplasia and substantially reduce the need for biopsies. Endomicroscopy is still mainly used for research but clinical acceptance is increasing because of a multitude of positive studies about

the diagnostic value of endomicroscopy. Different contrast agents are available to identify KU-60019 manufacturer cellular and subcellular structures. Fluorescent agents can also be combined with proteins or antibodies to enable molecular imaging. Smart biopsies, functional imaging (eg, defining local barrier dysfunction), and molecular imaging (predicting the response to biologic therapy) may represent

the future for endomicroscopy. “
“Resection of nonpolypoid lesions in inflammatory bowel disease (IBD) is among the most technically demanding of endoscopic procedures. Video of Endoscopic Submucosal Dissection (ESD) of a non-polypoid dysplastic lesion in ulcerative colitis accompanies this article at http://www.giendo.theclinics.com/ ABT-199 The risk of developing IBD-colitis-related colorectal cancer has been highlighted for many years. Early data suggested that the risk increased year on year with an 18% risk at 30 years1 and the initial British guidelines advocating shortening of surveillance Thymidine kinase intervals with each decade of disease.2 Subsequent data suggested the stronger influence of patient factors, including disease extent and activity, family history of colorectal cancer, endoscopic features (strictures or postinflammatory polyps) and previous dysplasia, rather than duration of disease alone, with the current generation of European guidelines advocating risk-based stratification.3, 4 and 5 More recently, some population-based studies have suggested

that previous results overestimate the risk of IBD dysplasia and cancer because of case selection from academic and tertiary centers.6 and 7 Alongside risk-based stratification, a new concept emerged for the management of polypoid dysplasia in IBD, in that polypoid circumscribed lesions (adenoma like masses) even within the colitic segment, might be safely managed by endoscopic resection and close follow-up rather than by panproctocolectomy.4 and 5 A recent meta-analysis of 10 studies with more than 370 patients and 1700 years of patient follow-up supports this concept: 5 (95% confidence interval, 3–10) cancers developed per 1000 years of patient follow-up.8 The rate of dysplasia detected at subsequent colonoscopy was 65 cases per 1000 years of patient follow-up, emphasizing that close colonoscopic surveillance is mandatory. However, all the studies in this meta-analysis predate the use of chromoendoscopy.